RxDoctor Payments Data

Stephanie Hoheisel

Primary Care · Columbus, OHNPI 1922533538

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,002 of the $2,227 with a category attached, or 89.9%. 9 manufacturers reported payments, led by Boston Scientific at 38.0% of the total. Reporting peaked in 2022 at $907 and has fallen 68.4% since, to $287 in 2024.

$2,227in general payments, 2019–2025

Across 68 payments — averaging $32.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$847
  • Amgen$361
  • Medtronic$291
  • AstraZeneca$288
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$253
  • Johnson & Johnson$129
  • plus $60 from 3 others

What the payments were for

  • Travel & lodging$251%
  • Food & beverage$2,00290%
  • Education$2009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,227 in reported general payments places this provider in the 80th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio

Medicare billing

Part B allowed, 2024
$8,541
Medicare patients
84
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$28,664
EntrestoSacubitril/Valsartan17$12,019
XareltoRivaroxaban13$10,339
FarxigaDapagliflozin Propanediol11$8,818
Nitroglycerin41$849
Metoprolol Succinate100$547
Atorvastatin Calcium71$437
Carvedilol40$265
ClopidogrelClopidogrel Bisulfate55$234
Lisinopril22$205
Isosorbide Mononitrate ErIsosorbide Mononitrate38$191
Ezetimibe13$162
Spironolactone19$138
Losartan Potassium20$130
Ranolazine ErRanolazine11$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$28,66438 claims
Johnson & JohnsonXarelto$129$10,33913 claims
AstraZenecaFarxiga$288$8,81811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 321 primary care providers in Ohio.

Other primary care in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →